(PharmaNewsWire.Com, August 21, 2018 ) Rubella Vaccine (Human Diploid Cell) market is anticipated to grow at XX % CAGR from 2018 to 2023 and it is estimated that the global market was valued at USD XX billion in 2018 and is expected to reach USD XX billion by 2023.
Rubella is an acute, viral, and contagious infection, which has a mild effect on children and is caused by the transmission of airborne droplets of infected people through sneezing or coughing. However, pregnant women suffering from rubella have to face severe consequences, as the viral infection results in death or congenital defects known as congenital rubella syndrome (CRS). Rubella vaccine has gained traction over the years as the disease is preventable only through vaccination and no other specific treatments exist for it.
The major factors that fuel the growth of the market are an increase in the incidence of rubella infection globally Approximately 100,000 infants are affected by rubella annually, thus increasing the government focus on rubella vaccination, which further propels the market growth. However, inherent disadvantages of using human diploid cell technology for constructing rubella vaccines such as high selectivity and insufficient yield, restrain the growth of the market. Conversely, ongoing R&D activities for the advancement of rubella vaccines are expected to offer lucrative opportunities for the growth of the market.
The global Rubella Vaccine market is segmented on the basis of End User. On the basis of End User, the market is segmented into Pediatric Rubella Vaccine, Adult Rubella Vaccine, and Traveler Rubella Vaccine.
On the basis of geography, the Rubella Vaccine market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America accounted for the largest share of the Rubella Vaccine market followed by Europe and Asia Pacific. Asia Pacific is expected to witness the highest CAGR in the coming years.
The market is dominated by companies like Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
